Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on JX10 for Improving Outcomes in Patients with Acute Ischemic Stroke

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a treatment called JX10 on patients who have experienced an acute ischemic stroke. An acute ischemic stroke occurs when a blood clot blocks a blood vessel in the brain, leading to a sudden loss of blood flow and potentially causing brain damage. The study aims to determine if JX10 can improve recovery and reduce symptoms in patients who have had this type of stroke.

Participants in the study will receive either the JX10 treatment or a placebo, which is a substance with no active medication. The treatment is given as an infusion, meaning it is administered directly into the bloodstream through a vein. The study will compare the outcomes of those receiving JX10 with those receiving the placebo to see if there is a significant difference in recovery and symptom improvement.

The study will monitor participants over a period of time to assess their recovery and any potential side effects, such as the risk of bleeding in the brain, known as intracranial hemorrhage. The main goal is to see if JX10 can help patients have fewer or milder symptoms 90 days after their stroke. Participants will be closely observed to ensure their safety and to gather information on how well the treatment works.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be required to provide written informed consent. This means you agree to participate after understanding the study's purpose and procedures.

    You must meet certain criteria, such as being between 18 and 90 years old and having experienced an acute ischemic stroke. Additional medical assessments will confirm your eligibility.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to evaluate your current health status. This includes a review of your medical history and a physical examination.

    Imaging tests, such as a CT or MRI scan, will be performed to assess the condition of your brain and blood vessels.

  3. Step 3

    Treatment administration

    You will receive either the study medication, JX10, or a placebo. A placebo is a substance with no active medication, used for comparison.

    JX10 is administered as a sterile powder mixed into a solution and given through an intravenous infusion. This means it is delivered directly into your bloodstream through a vein.

    The treatment will be administered within 4.5 to 24 hours after the onset of stroke symptoms, depending on your specific condition and imaging results.

  4. Step 4

    Monitoring and follow-up

    After receiving the treatment, you will be closely monitored for any changes in your condition. This includes regular check-ups and assessments of your neurological function.

    You will be observed for any side effects, particularly the risk of bleeding in the brain, which is a potential concern with this treatment.

  5. Step 5

    Final evaluation

    A final evaluation will be conducted 90 days after the treatment to assess your recovery and any lasting effects of the treatment.

    The primary goal is to determine if you have minimal or no symptoms and to evaluate the safety of the treatment.

Who can join the trial?

10 criteria

  • Age must be between 18 and 90 years old. If you are older than 85, you must have been fully independent before the stroke.
  • You or your legal representative must provide written consent to participate.
  • You must have an acute ischemic stroke, which is a type of stroke caused by a blockage in the blood vessels of the brain.
  • The stroke must be confirmed by specific imaging tests like CT Angiography (CTA) or Magnetic Resonance Angiography (MRA), which are scans that show blood flow in the brain.
  • There must be evidence of salvageable brain tissue, meaning parts of the brain that can still be saved, shown by specific imaging tests.
  • You must be able to start the study treatment within 4.5 to 6 hours after the stroke if no imaging is done, or within 4.5 to 24 hours if imaging shows salvageable tissue.
  • Your initial stroke severity score, called the NIH Stroke Scale (NIHSS), must be 5 or higher. This scale measures the effects of a stroke.
  • You must have been functionally independent before the stroke, meaning you could perform daily activities without help.
  • If you are a woman who can have children, you must have a negative pregnancy test and use effective birth control during the study and for 30 days after the last dose of the study treatment.
  • If you are a man, you must use effective birth control during the study and for 90 days after the last dose of the study treatment. You should not donate sperm during this time.

Who cannot join the trial?

10 criteria

  • Patients who have had a **recent head injury** or **brain surgery**.
  • Patients with a **history of bleeding disorders**. This means any condition that makes it hard for the blood to clot.
  • Patients who are currently taking **blood thinners**. These are medications that prevent blood clots.
  • Patients with **severe liver or kidney disease**. This refers to serious problems with the liver or kidneys.
  • Patients who have had a **major surgery** in the last 30 days.
  • Patients with **uncontrolled high blood pressure**. This means blood pressure that is not managed well with medication.
  • Patients who are **pregnant or breastfeeding**.
  • Patients with a **known allergy** to the study medication or its ingredients.
  • Patients who have participated in another clinical trial in the last 30 days.
  • Patients with a **serious infection**. This means an infection that requires treatment with antibiotics or other medications.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

JX10 is a medication being tested to see if it can help people who have had a type of stroke called an acute ischemic stroke. This kind of stroke happens when a blood clot blocks blood flow to the brain. The study is looking at whether JX10 can improve how well people recover and function after having this kind of stroke. Researchers are also checking if JX10 increases the risk of bleeding in the brain, which is a possible side effect. The goal is to find out if JX10 can help people recover better from strokes without causing serious side effects.

What is already known about the treatment

JX10 – JX10 is administered to patients through an intravenous infusion, which means it is delivered directly into the bloodstream through a vein. Currently, JX10 is being studied in clinical trials to assess its effectiveness and safety for treating acute ischemic stroke, a condition where blood flow to the brain is blocked. The main goal of using JX10 is to improve recovery and neurological function in patients who experience this type of stroke, especially those who seek treatment later than usual. At the molecular level, JX10 works by enhancing blood flow to the affected areas of the brain, potentially reducing damage and improving outcomes. It is classified as a therapeutic agent aimed at improving blood circulation and reducing the risk of further complications in stroke patients.

Investigated diseases

Acute ischemic stroke – Acute ischemic stroke occurs when a blood clot blocks or narrows an artery leading to the brain, causing a sudden reduction in blood flow. This interruption in blood supply results in the deprivation of oxygen and nutrients to brain tissue, leading to the death of brain cells. The progression of the disease can lead to sudden numbness or weakness, especially on one side of the body, confusion, trouble speaking, or difficulty understanding speech. Other symptoms may include vision problems, dizziness, loss of balance, or severe headache. The severity and specific symptoms depend on the location and extent of the brain affected. Immediate medical attention is crucial to minimize brain damage and potential complications.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IVTrial ID2024-519521-37-01Protocol codeJX10002Estimated enrolment881 patientsSponsorCorxel Pharmaceuticals Co. Ltd.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.